Matinas BioPharma downgraded to Neutral from Buy at Alliance Global Partners
The Fly

Matinas BioPharma downgraded to Neutral from Buy at Alliance Global Partners

Alliance Global Partners downgraded Matinas BioPharma (MTNB) to Neutral from Buy without a price target after the company announced that negotiations under the previously disclosed non-binding term sheet regarding marketing rights to its oral formulation of amphotericin B have been terminated by the prospective partner. Matinas has implemented an 80% workforce reduction as a result of this event, the analyst tells investors in a research note. The firm says “this is a material negative event for the company that introduces significant uncertainty.” Alliance Global suspects Matinas “is stretching its runway to try and sell/partner the asset.”

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App